Portrait de David Buckeridge

David Buckeridge

Membre académique associé
Professeur titulaire, McGill University, Département d'épidémiologie, biostatistique et santé au travail
Google Scholar
LinkedIn

Biographie

David Buckeridge est professeur titulaire à l'École de santé des populations et de santé mondiale de l'Université McGill, responsable de la santé numérique au Centre universitaire de santé McGill et directeur scientifique exécutif pour l'Agence de la santé publique du Canada. Titulaire d'une chaire de recherche du Canada (niveau 1) en informatique de la santé et en science des données, il a établi les projections concernant la demande dans le système de santé du Québec, dirigé la gestion des données et l'analyse pour le groupe de travail sur l'immunité canadienne et aidé l'Organisation mondiale de la santé à surveiller l'immunité mondiale contre le SRAS-CoV-2. Il est titulaire d'un doctorat en médecine (Université Queen's), d'une maîtrise en épidémiologie (Université de Toronto) et d'un doctorat en informatique biomédicale (Université Stanford), et est membre du Collège royal des médecins du Canada.

Étudiants actuels

Eva Gao
Doctorat - McGill University
eva.gao@mila.quebec
Gabriel Potvin
Maîtrise recherche - McGill University
gabriel.potvin@mila.quebec
Kalash Dave
Maîtrise recherche - McGill University
dave.kalash@mila.quebec
Rada Rusu
Maîtrise recherche - McGill University
rada.rusu@mila.quebec
Yannan Shen
Maîtrise recherche - McGill University
yannan.shen@mila.quebec

Publications

Exploring social inequalities in healthcare trajectories following diagnosis of diabetes: a state sequence analysis of linked survey and administrative data
Rachel McKay
Laurence Letarte
Alain Gillian Lucie David Manon Catherine Anaïs Benoit A Vanasse Bartlett Blais Buckeridge Choinière Hudon
Alain Gillian Lucie David Manon Catherine Anaïs Benoit Alexandre Amélie Pasquale Valérie Marie-Pascale Mike Anne-Marie Marc Josiane Mireille Stéphanie Pierre Annie Isabelle Danielle Denis Jaime André Geneviève Jean-François Roxanne Marc-Antoine Pier Sonia Vanasse
Alain Vanasse
Gillian Bartlett
Lucie Blais
David Buckeridge
Manon Choinière
Catherine Hudon
Anaïs Lacasse
Benoit Lamarche
Alexandre Lebel
Amélie Quesnel-Vallée
Pasquale Roberge
Valérie Émond
Marie-Pascale Pomey
Mike Benigeri
Anne-Marie Cloutier
Marc Dorais … (voir 16 de plus)
Josiane Courteau
Mireille Courteau
Stéphanie Plante
Pierre Cambon
Annie Giguère
Isabelle Leroux
Danielle St-Laurent
Denis Roy
Jaime Borja
André Néron
Geneviève Landry
Jean-François Ethier
Roxanne Dault
Marc-Antoine Côté-Marcil
Pier Tremblay
Sonia Quirion
2022-01-31
BMC Health Services Research (publié)
doi.org
Global variation in event-based surveillance for disease outbreak detection: A time series analysis (Preprint)
Iris Ganser
Rodolphe Thiébaut
David Buckeridge
BACKGROUND Robust and flexible infectious disease surveillance is crucial for public health. Event-based surveillance (EBS) was developed t… (voir plus)o allow timely detection of infectious disease outbreaks using mostly web-based data. Despite its widespread use, EBS has not been evaluated systematically on a global scale in terms of outbreak detection performance. OBJECTIVE To assess the variation in timing and frequency of EBS reports compared to true outbreaks and to identify the determinants of variability, using the example of seasonal influenza epidemics in 24 countries. METHODS We obtained influenza-related reports from two EBS systems, HealthMap and the WHO Epidemic Intelligence from Open Sources (EIOS), and weekly virologic influenza counts from FluNet as a gold standard. Epidemic influenza periods were detected based on report frequency using Bayesian change point analysis. Timely sensitivity, i.e., outbreak detection within the first two weeks before or after an outbreak onset, was calculated along with sensitivity, specificity, positive predictive value, and timeliness of detection. Linear regressions were performed to assess the influence of country-specific factors on EBS performance. RESULTS Overall, monitoring the frequency of EBS reports detected 73.5% of outbreaks, but only 9.2% within two weeks of onset; in the best case, monitoring the frequency of health-related reports identified 29% of outbreaks within two weeks of onset. We observed a large degree of variability in all evaluation metrics across countries. The number of EBS reports available within a country, the human development index, and the country’s geographical location partially explained this variability. CONCLUSIONS Monitoring the frequency of EBS reports allowed just under 10% of seasonal influenza outbreaks to be detected in a timely manner in a worldwide analysis, with a large variability in detection capabilities. This article documents the global variation of EBS performance and demonstrates that monitoring report frequency alone in EBS may be insufficient for timely detection of outbreaks. Moreover, factors such as human development index and geographical location of a country may influence the performance of EBS and should be considered in future evaluations.
2022-01-05
(publié)
doi.org
Global variation in event-based surveillance for disease outbreak detection: A time series analysis (Preprint)
Iris Ganser
R. Thiébaut
David Buckeridge
BACKGROUND Robust and flexible infectious disease surveillance is crucial for public health. Event-based surveillance (EBS) was developed t… (voir plus)o allow timely detection of infectious disease outbreaks using mostly web-based data. Despite its widespread use, EBS has not been evaluated systematically on a global scale in terms of outbreak detection performance. OBJECTIVE To assess the variation in timing and frequency of EBS reports compared to true outbreaks and to identify the determinants of variability, using the example of seasonal influenza epidemics in 24 countries. METHODS We obtained influenza-related reports from two EBS systems, HealthMap and the WHO Epidemic Intelligence from Open Sources (EIOS), and weekly virologic influenza counts from FluNet as a gold standard. Epidemic influenza periods were detected based on report frequency using Bayesian change point analysis. Timely sensitivity, i.e., outbreak detection within the first two weeks before or after an outbreak onset, was calculated along with sensitivity, specificity, positive predictive value, and timeliness of detection. Linear regressions were performed to assess the influence of country-specific factors on EBS performance. RESULTS Overall, monitoring the frequency of EBS reports detected 73.5% of outbreaks, but only 9.2% within two weeks of onset; in the best case, monitoring the frequency of health-related reports identified 29% of outbreaks within two weeks of onset. We observed a large degree of variability in all evaluation metrics across countries. The number of EBS reports available within a country, the human development index, and the country’s geographical location partially explained this variability. CONCLUSIONS Monitoring the frequency of EBS reports allowed just under 10% of seasonal influenza outbreaks to be detected in a timely manner in a worldwide analysis, with a large variability in detection capabilities. This article documents the global variation of EBS performance and demonstrates that monitoring report frequency alone in EBS may be insufficient for timely detection of outbreaks. Moreover, factors such as human development index and geographical location of a country may influence the performance of EBS and should be considered in future evaluations.
2022-01-05
(published)
doi.org
Global Variations in Event-Based Surveillance for Disease Outbreak Detection: Time Series Analysis
Iris Ganser
Rodolphe Thiébaut
David Buckeridge
2022-01-05
JMIR Public Health and Surveillance (publié)
doi.org
Global Variations in Event-Based Surveillance for Disease Outbreak Detection: Time Series Analysis
Iris Ganser
R. Thiébaut
David Buckeridge
Background Robust and flexible infectious disease surveillance is crucial for public health. Event-based surveillance (EBS) was developed to… (voir plus) allow timely detection of infectious disease outbreaks by using mostly web-based data. Despite its widespread use, EBS has not been evaluated systematically on a global scale in terms of outbreak detection performance. Objective The aim of this study was to assess the variation in the timing and frequency of EBS reports compared to true outbreaks and to identify the determinants of variability by using the example of seasonal influenza epidemic in 24 countries. Methods We obtained influenza-related reports between January 2013 and December 2019 from 2 EBS systems, that is, HealthMap and the World Health Organization Epidemic Intelligence from Open Sources (EIOS), and weekly virological influenza counts for the same period from FluNet as the gold standard. Influenza epidemic periods were detected based on report frequency by using Bayesian change point analysis. Timely sensitivity, that is, outbreak detection within the first 2 weeks before or after an outbreak onset was calculated along with sensitivity, specificity, positive predictive value, and timeliness of detection. Linear regressions were performed to assess the influence of country-specific factors on EBS performance. Results Overall, while monitoring the frequency of EBS reports over 7 years in 24 countries, we detected 175 out of 238 outbreaks (73.5%) but only 22 out of 238 (9.2%) within 2 weeks before or after an outbreak onset; in the best case, while monitoring the frequency of health-related reports, we identified 2 out of 6 outbreaks (33%) within 2 weeks of onset. The positive predictive value varied between 9% and 100% for HealthMap and from 0 to 100% for EIOS, and timeliness of detection ranged from 13% to 94% for HealthMap and from 0% to 92% for EIOS, whereas system specificity was generally high (59%-100%). The number of EBS reports available within a country, the human development index, and the country’s geographical location partially explained the high variability in system performance across countries. Conclusions We documented the global variation of EBS performance and demonstrated that monitoring the report frequency alone in EBS may be insufficient for the timely detection of outbreaks. In particular, in low- and middle-income countries, low data quality and report frequency impair the sensitivity and timeliness of disease surveillance through EBS. Therefore, advances in the development and evaluation and EBS are needed, particularly in low-resource settings.
2022-01-05
JMIR Public Health and Surveillance (published)
doi.org
Usefulness of School Absenteeism Data for Predicting Infl uenza Outbreaks,
Joseph R. Egger
A. Hoen
John S. Brownstein
David Buckeridge
Donald R. Olson
Kevin James Konty
and second-round PCR were 94°C for 3 min, followed by 40 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 2 min. Expected amplifi ca… (voir plus)tion products were 458 bp (PCR-1) and 304 bp (PCR-2). Using dilutions of a synthetic template corresponding to the target sequence, we estimated the sensitivity of the amplifi cation assay to be 5 copies of target sequence by limiting-dilution assay. Negative (sterile water) and positive controls (synthetic template dilutions) were
2022-01-01
(publié)
www.semanticscholar.org
COVID-19 Seroprevalence in Canada Modelling Waning and Boosting COVID-19 Immunity in Canada a Canadian Immunization Research Network Study
David W. Dick
Lauren Childs
Zhilan Feng
Jing Li
Gergely Röst
David Buckeridge
Nick H. Ogden
Jane Heffernan
2021-12-23
Vaccines (publié)
doi.org
Fall 2021 Resurgence and COVID-19 Seroprevalence in Canada: Modelling waning and boosting COVID-19 immunity in Canada, A Canadian Immunization Research Network Study
David W. Dick
Lauren Childs
Zhilan Feng
Jing Li
Gergely Röst
David Buckeridge
Nick H. Ogden
Jane Heffernan
2021-12-23
Vaccines (publié)
doi.org
Global epidemiology of SARS-CoV-2 infection: a systematic review and meta-analysis of standardized population-based seroprevalence studies, Jan 2020-Oct 2021
Isabel Bergeri
Mairead Whelan
Harriet Ware
Lorenzo Subissi
Anthony Nardone
H. Lewis
Zihan Li
Xiaomeng Ma
Marta Valenciano
Brianna Cheng
Lubna Al Ariqi
Arash Rashidian
Joseph Okeibunor
Tasnim Azim
Pushpa Wijesinghe
Linh-Vi Le
Aisling Vaughan
Richard Pebody
Andrea Vicari
Tingting Yan … (voir 8 de plus)
Mercedes Yanes-Lane
Christian Cao
Matthew P. Cheng
Jesse Papenburg
David Buckeridge
Niklas Bobrovitz
Rahul K. Arora
Maria D Van Kerkhove
Background COVID-19 case data underestimates infection and immunity, especially in low- and middle-income countries (LMICs). We meta-analyze… (voir plus)d standardized SARS-CoV-2 seroprevalence studies to estimate global seroprevalence. Objectives/Methods We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence studies aligned with the WHO UNITY protocol published between 2020-01-01 and 2021-10-29. Eligible studies were extracted and critically appraised in duplicate. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate under-ascertainment; meta-analyzed differences in seroprevalence between demographic subgroups; and identified national factors associated with seroprevalence using meta-regression. PROSPERO: CRD42020183634. Results We identified 396 full texts reporting 736 distinct seroprevalence studies (41% LMIC), including 355 low/moderate risk of bias studies with national/sub-national scope in further analysis. By April 2021, global SARS-CoV-2 seroprevalence was 26.1%, 95% CI [24.6-27.6%]. Seroprevalence rose steeply in the first half of 2021 due to infection in some regions (e.g., 18.2% to 45.9% in Africa) and vaccination and infection in others (e.g., 11.3% to 57.4% in the Americas high-income countries), but remained low in others (e.g., 0.3% to 1.6% in the Western Pacific). In 2021 Q1, median seroprevalence to case ratios were 1.9:1 in HICs and 61.9:1 in LMICs. Children 0-9 years and adults 60+ were at lower risk of seropositivity than adults 20-29. In a multivariate model using data pre-vaccination, more stringent public health and social measures were associated with lower seroprevalence. Conclusions Global seroprevalence has risen considerably over time and with regional variation, however much of the global population remains susceptible to SARS-CoV-2 infection. True infections far exceed reported COVID-19 cases. Standardized seroprevalence studies are essential to inform COVID-19 control measures, particularly in resource-limited regions.
2021-12-15
medRxiv (prépublication)
doi.org
Mortality trends and lengths of stay among hospitalized COVID-19 patients in Ontario and Quebec (Canada): a population-based cohort study of the first three epidemic waves
Yiqing Xia
Huiting Ma
David Buckeridge
Marc Brisson
Beate Sander
Adrienne K. Chan
Aman D Verma
Iris Ganser
Nadine Kronfli
Sharmistha Mishra
Mathieu Maheu‐giroux
Background: Epidemic waves of COVID-19 strained hospital resources. We describe temporal trends in mortality risk and length of stay in inte… (voir plus)nsive cares units (ICUs) among COVID-19 patients hospitalized through the first three epidemic waves in Canada. Methods: We used population-based provincial hospitalization data from Ontario and Qu&eacutebec to examine mortality risk and lengths of ICU stay. For each province, adjusted estimates were obtained using marginal standardization of logistic regression models, adjusting for patient-level characteristics and hospital-level determinants. Results: Using all hospitalizations from Ontario (N=26,541) and Qu&eacutebec (N=23,857), we found that unadjusted in-hospital mortality risks peaked at 31% in the first wave and was lowest at the end of the third wave at 6-7%. This general trend remained after controlling for confounders. The odds of in-hospital mortality in the highest hospital occupancy quintile was 1.2 (95%CI: 1.0-1.4; Ontario) and 1.6 (95%CI: 1.3-1.9; Qu&eacutebec) times that of the lowest quintile. Variants of concerns were associated with an increased in-hospital mortality. Length of ICU stay decreased over time from a mean of 16 days (SD=18) to 15 days (SD=15) in the third wave but were consistently higher in Ontario than Qu&eacutebec by 3-6 days. Conclusion: In-hospital mortality risks and lengths of ICU stay declined over time in both provinces, despite changing patient demographics, suggesting that new therapeutics and treatment, as well as improved clinical protocols, could have contributed to this reduction. Continuous population-based monitoring of patient outcomes in an evolving epidemic is necessary for health system preparedness and response.
2021-12-08
medRxiv (prépublication)
doi.org
Opioid prescribing among new users for non-cancer pain in the USA, Canada, UK, and Taiwan: A population-based cohort study
Meghna Jani
Nadyne Girard
David W. Bates
David Buckeridge
Therese Sheppard
Jack Li
Usman Iqbal
Shelly Vik
Colin Weaver
Judy Seidel
William G. Dixon
Robyn Tamblyn
Background The opioid epidemic in North America has been driven by an increase in the use and potency of prescription opioids, with ensuing … (voir plus)excessive opioid-related deaths. Internationally, there are lower rates of opioid-related mortality, possibly because of differences in prescribing and health system policies. Our aim was to compare opioid prescribing rates in patients without cancer, across 5 centers in 4 countries. In addition, we evaluated differences in the type, strength, and starting dose of medication and whether these characteristics changed over time. Methods and findings We conducted a retrospective multicenter cohort study of adults who are new users of opioids without prior cancer. Electronic health records and administrative health records from Boston (United States), Quebec and Alberta (Canada), United Kingdom, and Taiwan were used to identify patients between 2006 and 2015. Standard dosages in morphine milligram equivalents (MMEs) were calculated according to The Centers for Disease Control and Prevention. Age- and sex-standardized opioid prescribing rates were calculated for each jurisdiction. Of the 2,542,890 patients included, 44,690 were from Boston (US), 1,420,136 Alberta, 26,871 Quebec (Canada), 1,012,939 UK, and 38,254 Taiwan. The highest standardized opioid prescribing rates in 2014 were observed in Alberta at 66/1,000 persons compared to 52, 51, and 18/1,000 in the UK, US, and Quebec, respectively. The median MME/day (IQR) at initiation was highest in Boston at 38 (20 to 45); followed by Quebec, 27 (18 to 43); Alberta, 23 (9 to 38); UK, 12 (7 to 20); and Taiwan, 8 (4 to 11). Oxycodone was the first prescribed opioid in 65% of patients in the US cohort compared to 14% in Quebec, 4% in Alberta, 0.1% in the UK, and none in Taiwan. One of the limitations was that data were not available from all centers for the entirety of the 10-year period. Conclusions In this study, we observed substantial differences in opioid prescribing practices for non-cancer pain between jurisdictions. The preference to start patients on higher MME/day and more potent opioids in North America may be a contributing cause to the opioid epidemic.
2021-11-01
PLoS Medicine (publié)
doi.org
Evaluating Montréal’s harm reduction interventions for people who inject drugs: protocol for observational study and cost-effectiveness analysis
Dimitra Panagiotoglou
Michal Abrahamowicz
David Buckeridge
J Jaime Caro
Eric Latimer
Mathieu Maheu-Giroux
Erin C Strumpf
2021-10-26
BMJ Open (publié)
doi.org